A phase 3 trial of lenalidomide / dexamethasone with elotuzumab (Empliciti ™), an antibody therapy that
attacks myeloma cells directly and spurs the immune system to launch an attack of its own.
By attaching to the myeloma cells, it marks them for destruction, and by attaching to NK cells, it primes the immune cells to search for and
attack the myeloma cells
This enhances the immune response through multiple mechanisms: by attaching to the myeloma cells, it marks them for destruction, and by attaching to the NK cells, it primes the immune cells to search for and
attack the myeloma cells.
Not exact matches
Whether investigating fat cells, immunotherapy or use of the CRISPR - Cas 9 gene - editing tool, which a federal panel recently approved for a select number of patients suffering from three types of cancers, including multiple
myeloma, approaches beyond
attacking cancer cells are needed in the fight against many cancers.
Targeted therapy — the most recent advancement in multiple
myeloma treatment, targeted therapies detect and
attack cancer cells without damaging normal cells